Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 8;15(4):470.
doi: 10.3390/genes15040470.

Detection of Macrolide and/or Fluoroquinolone Resistance Genes in Mycoplasma genitalium Strains Isolated from Men in the Northwest Region of Croatia in 2018-2023

Sunčanica Ljubin-Sternak  1   2 , Tomislav Meštrović  3   4 , Tatjana Marijan  1 , Maja Anušić  1 , Sandra Šuto  1 , Jasmina Vraneš  1   2
Affiliations

Detection of Macrolide and/or Fluoroquinolone Resistance Genes in Mycoplasma genitalium Strains Isolated from Men in the Northwest Region of Croatia in 2018-2023

Sunčanica Ljubin-Sternak et al. Genes (Basel). .

Abstract

Mycoplasma genitalium (M. genitalium) poses a significant public health challenge due to its association with non-gonococcal urethritis (particularly in men) and antimicrobial resistance. However, despite the prevalence of M. genitalium infections and the rise in resistance rates, routine testing and surveillance remain limited. This is the first study from Croatia that aimed to assess the prevalence and trends of resistance in M. genitalium strains isolated from male individuals by detecting macrolide and fluoroquinolone resistance genes. The study also aimed to explore the factors associated with resistance and changes in resistance patterns over time. Urine samples collected from male individuals in the Zagreb County and northwest region of Croatia between 2018 and 2023 were tested for M. genitalium with the use of molecular methods. Positive samples were subjected to DNA extraction and multiplex tandem polymerase chain reaction (MT-PCR) targeting genetic mutations associated with macrolide (23S rRNA gene) and fluoroquinolone (parC gene) resistance. Of the 8073 urine samples tested from 6480 male individuals (and following the exclusion of repeated specimens), we found that the prevalence of M. genitalium infection was 2.2%. Macrolide resistance was observed in 60.4% of strains, while fluoroquinolone resistance was found in 19.2%. Co-resistance to both antibiotics was present in 18.2% of cases. A statistically significant increase in fluoroquinolone resistance was noted over the study period (p = 0.010), but this was not evident for azithromycin resistance (p = 0.165). There were no statistically significant differences in resistance patterns between age groups, whereas re-testing of patients revealed dynamic changes in resistance profiles over time. The high burden of macrolide resistance and increasing fluoroquinolone resistance underscore the urgent need for comprehensive resistance testing and surveillance programs. The implementation of resistance-guided treatment strategies, along with enhanced access to molecular diagnostics, is pivotal for effectively managing M. genitalium infections.

Keywords: Mycoplasma genitalium; antimicrobial resistance; fluoroquinolones; macrolides; men; molecular testing; polymerase chain reaction (PCR); resistance genes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Conceptual framework of the research.
Figure 2
Figure 2
Year-by-year breakdown of macrolide and fluoroquinolone resistance for Mycoplasma genitalium strains isolated from urine samples of male study participants.
Figure 3
Figure 3
The number and resistance pattern of Mycoplasma genitalium strains isolated from urine samples of re-tested male study participants. Legend: MR—macrolide resistant; MS—macrolide sensitive; FR—fluoroquinolone resistant; FS—fluoroquinolone sensitive.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Jensen J.S., Cusini M., Gomberg M.A., Moi H., Wilson J., Unemo M. 2021 European Guideline on the Management of Mycoplasma genitalium Infections. J. Eur. Acad. Dermatol. Venereol. 2022;36:641–650. doi: 10.1111/jdv.17972. - DOI - PubMed
    1. Waites K.B., Crabb D.M., Ratliff A.E., Geisler W.M., Atkinson T.P., Xiao L. Latest Advances in Laboratory Detection of Mycoplasma genitalium. J. Clin. Microbiol. 2023;61:e0079021. doi: 10.1128/jcm.00790-21. - DOI - PMC - PubMed
    1. Mitjà O., Suñer C., Giacani L., Vall-Mayans M., Tiplica G.S., Ross J., Bradshaw C. Treatment of bacterial sexually transmitted infections in Europe: Gonorrhoea, Mycoplasma genitalium, and syphilis. Lancet Reg. Health Eur. 2023;34:100737. doi: 10.1016/j.lanepe.2023.100737. - DOI - PMC - PubMed
    1. Hetem D.J., Wessel S.K., Bruisten S.M., Braam J.F., Van Rooijen M.S., Vergunst C.E., Nijhuis R.H.T., Berns M., Brand J.-M., Van Dam A.P. High prevalence and resistance rates of Mycoplasma genitalium among patients visiting two sexually transmitted infection clinics in the Netherlands. Int. J. STD AIDS. 2021;32:837–844. doi: 10.1177/0956462421999287. - DOI - PubMed
    1. Bradshaw C.S., Chen M.Y., Fairley C.K. Persistence of Mycoplasma genitalium following azithromycin therapy. PLoS ONE. 2008;3:e3618. doi: 10.1371/journal.pone.0003618. - DOI - PMC - PubMed

Publication types

MeSH terms